Nieuws uit het hoofdkantoor in Tokio

Fujifilm to Invest USD 1.6 billion to enhance and expand its global offering of cell culture manufacturing services

Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.

Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business
Amendment in relation to a return of domestic marketing rights for a product

Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.

Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business to PeptiDream

Launch of Therapeutic Radiopharmaceutical Product, Lutathera^® Injection targeting neuroendocrine tumors in Japan (FUJIFILM Toyama Chemical)

$850 Million USD (¥90 Billion Yen) investment in FUJIFILM Diosynth Biotechnologies to add additional development and manufacturing capacity

Marketing Authorization Granted for Lutathera^® Injection in Japan
- The first approval in Japan for peptide receptor radionuclide treatment drug, providing a new therapeutic option for neuroendocrine tumors (FUJIFILM Toyama Chemical)

FUJIFILM Healthcare starts to operate as Fujifilm Group company

Fujifilm launches “FUJIFILM COVID-19 Ag Test”, a SARS-CoV-2 antigen rapid diagnostic test with a highly-sensitive detection technology based on silver halide amplification, in Europe

Fujifilm Selects North Carolina as the Location to Build the Largest Cell Culture Biopharmaceutical CDMO Facility in North America

Notice Concerning the Completion Timing for the Acquisition of Hitachi’s Diagnostic Imaging-related Business

Fujifilm Kyowa Kirin Biologics and Mylan EPD Announce Launch of “Adalimumab (Genetical Recombination) [Adalimumab Biosimilar 1]” in Japan

Transfer of Shares in Japan Tissue Engineering Co., Ltd. to TEIJIN LIMITED

Fujifilm and the Center for Advanced Biological Innovation and Manufacturing Announce 76 million USD in Funding for Manufacturing and Innovation Center

Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.

Fujifilm to invest $40 Million to Establish a New State-of-the-Art Viral Vector and Advanced Therapy Process Development and Manufacturing Facility

FUJIFILM Diosynth Biotechnologies Stands Ready to Manufacture Lilly COVID-19 Antibody for Low- and Middle-Income Countries

Fujifilm to Expand its Viral Vector CDMO Services to Europe

Centus Biotherapeutics Receives European Marketing Authorization for Equidacent^®, Biosimilar Avastin^®